Pavmed Inc Stock Performance
| PAVM Stock | USD 0.97 0.03 3.19% |
The firm holds a Beta of -1.45, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning PAVmed are expected to decrease by larger amounts. On the other hand, during market turmoil, PAVmed is expected to outperform it. At this point, PAVmed Inc has a negative expected return of -0.0486%. Please make sure to check PAVmed's downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to decide if PAVmed Inc performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days PAVmed Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, PAVmed is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:15 | Last Split Date 2023-12-07 |
1 | PAVmed Inc Shares Up 9.17 percent on Sep 9 | 09/09/2024 |
2 | Lucid Diagnostics to be deconsolidated from PAVmeds financial statements - Seeking Alpha | 09/17/2024 |
3 | Acquisition by Agrawal Sundeep of 205000 shares of PAVmed at 1.63 subject to Rule 16b-3 | 09/19/2024 |
4 | American Foregut Societys 2024 Annual Meeting to Highlight Lucid Diagnostics EsoGuard Esophageal Precancer Test | 09/24/2024 |
5 | Discretionary transaction by Sirovich Matthew of tradable shares of PAVmed subject to Rule 16b-3 | 10/04/2024 |
6 | PAVmed Subsidiary, Veris Health, Awarded 1.8 Million NIH Grant to Enhance Cancer Care | 10/10/2024 |
7 | Acquisition by Agrawal Sundeep of 50000 shares of PAVmed at 1.04 subject to Rule 16b-3 | 10/21/2024 |
8 | Acquisition by Battleman David S. of 200000 shares of PAVmed at 1.0 subject to Rule 16b-3 | 10/24/2024 |
9 | NeuroPace, Inc. Reports Q3 Loss, Tops Revenue Estimates | 11/12/2024 |
10 | PAVmed Non-GAAP EPS of -0.54 beats by 0.76, revenue of 0.99M misses by 0.1M | 11/14/2024 |
11 | PAVmed Inc. Q3 2024 Earnings Call Transcript | 11/15/2024 |
12 | PAVmed Closes on Sale of Lucid Diagnostics Senior Secured Convertible Notes | 11/29/2024 |
| Begin Period Cash Flow | 39.7 M |
PAVmed |
PAVmed Relative Risk vs. Return Landscape
If you would invest 119.00 in PAVmed Inc on September 2, 2024 and sell it today you would lose (22.00) from holding PAVmed Inc or give up 18.49% of portfolio value over 90 days. PAVmed Inc is currently does not generate positive expected returns and assumes 7.7621% risk (volatility on return distribution) over the 90 days horizon. In different words, 69% of stocks are less volatile than PAVmed, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
PAVmed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PAVmed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as PAVmed Inc, and traders can use it to determine the average amount a PAVmed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0063
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PAVM |
Estimated Market Risk
| 7.76 actual daily | 69 69% of assets are less volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average PAVmed is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PAVmed by adding PAVmed to a well-diversified portfolio.
PAVmed Fundamentals Growth
PAVmed Stock prices reflect investors' perceptions of the future prospects and financial health of PAVmed, and PAVmed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PAVmed Stock performance.
| Return On Equity | -13.58 | ||||
| Return On Asset | -0.8 | ||||
| Operating Margin | (13.98) % | ||||
| Current Valuation | 47.82 M | ||||
| Shares Outstanding | 10.74 M | ||||
| Price To Earning | (6.39) X | ||||
| Price To Book | 7.42 X | ||||
| Price To Sales | 2.72 X | ||||
| Revenue | 2.45 M | ||||
| Gross Profit | (3.24 M) | ||||
| EBITDA | (75.74 M) | ||||
| Net Income | (64.17 M) | ||||
| Cash And Equivalents | 68.47 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 48.73 M | ||||
| Debt To Equity | 0.79 % | ||||
| Current Ratio | 1.82 X | ||||
| Book Value Per Share | (6.62) X | ||||
| Cash Flow From Operations | (52.04 M) | ||||
| Earnings Per Share | (1.14) X | ||||
| Market Capitalization | 10.42 M | ||||
| Total Asset | 33.12 M | ||||
| Retained Earnings | (294.43 M) | ||||
| Working Capital | (29.68 M) | ||||
| Current Asset | 1.97 M | ||||
| Current Liabilities | 842 K | ||||
About PAVmed Performance
By examining PAVmed's fundamental ratios, stakeholders can obtain critical insights into PAVmed's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that PAVmed is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 30.64 | 29.11 | |
| Return On Tangible Assets | (2.02) | (2.13) | |
| Return On Capital Employed | 3.27 | 3.10 | |
| Return On Assets | (1.94) | (2.03) | |
| Return On Equity | 1.19 | 1.13 |
Things to note about PAVmed Inc performance evaluation
Checking the ongoing alerts about PAVmed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for PAVmed Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PAVmed Inc generated a negative expected return over the last 90 days | |
| PAVmed Inc has high historical volatility and very poor performance | |
| PAVmed Inc has some characteristics of a very speculative penny stock | |
| PAVmed Inc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 2.45 M. Net Loss for the year was (64.17 M) with loss before overhead, payroll, taxes, and interest of (3.24 M). | |
| PAVmed Inc currently holds about 68.47 M in cash with (52.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| PAVmed Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: PAVmed Closes on Sale of Lucid Diagnostics Senior Secured Convertible Notes |
- Analyzing PAVmed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PAVmed's stock is overvalued or undervalued compared to its peers.
- Examining PAVmed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PAVmed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PAVmed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PAVmed's stock. These opinions can provide insight into PAVmed's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PAVmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PAVmed. If investors know PAVmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PAVmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.14) | Revenue Per Share 0.459 | Quarterly Revenue Growth 4.898 | Return On Assets (0.80) | Return On Equity (13.58) |
The market value of PAVmed Inc is measured differently than its book value, which is the value of PAVmed that is recorded on the company's balance sheet. Investors also form their own opinion of PAVmed's value that differs from its market value or its book value, called intrinsic value, which is PAVmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PAVmed's market value can be influenced by many factors that don't directly affect PAVmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PAVmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if PAVmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PAVmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.